Published in Medical Verdicts and Law Weekly, July 26th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at GlaxoSmithKline.
Report 1: GlaxoSmithKline and Adolor Corporation today provided an update on the alvimopan (Entereg/Entrareg(R)) development programme.
The U.S. Food and Drug Administration (FDA) has requested that additional data be submitted as part of the complete response to the November 6, 2006approvable letter for alvimopan in postoperative ileus (POI). These additional data includethe final results of Study 101684, an extension of the Phase 2b Study 008 of alvimopan in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly